AtlanGRAM
In vivo & in vitro
Antibacterial Efficacy Studies
ATLANGRAM EXPERTISE
ATLANGRAM is specializing in preclinical efficacy testing of antibacterial agents thanks to its comprehensive In vitro and In vivo studies (screening & discriminant models). Thus, we can provide recommendations on optimal dose, on administration route and/or frequency, and finally, on bacterial targets and future development/indications of the compound.
EVALUATION
Our offer is comprehensive and consists of a wide range of microbiology studies to assess in vitro and in vivo efficacy activities of an antibacterial agent.
20+ years Efficacy Expertise
500+ Characterized Strains
12+ Mouse & Rabbit Models
300+ Communications/Publications
OPTIMISATION
We use the Nano-Encapsulation in Lipid Nano-Capsules (LNCs), an innovative technology to improve antibacterial efficacy and tolerance.
Passive targeting
Stealth and Biodegradable
Easy manufacturing
Safe and non-expensive
BENEFIT FROM CRÉDIT IMPÔTS RECHERCHE
ATLANGRAM has been accredited for the French R&D tax credit (Crédit d’Impôt Recherche, CIR) by the French Ministry of Higher Education and Research.
OUR PARTNERS
ATLANGRAM is based at Nantes (France), a city which offers opportunities to conduct collaborative projects with the Nantes University, MedQual (an epidemiological network with a bank of hospital and community bacterial strains), and Atlanpole Biotherapies (a regional cluster). Bpifrance, the Region Pays de la Loire and Total Development have granted to ATLANGRAM a financial assistance.
LAST PUBLICATIONS
ATLANGRAM scientific team has published in international scientific journals (PLoS One, AAC, JAC etc.) and communicated at various conferences such as ICAAC, ASM and ECCMID. Here are our last publications.
"2019 - Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination. Antimicrob Agents Chemother"
, , , , , , , , ,, , ,
"2016 - New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection"
M. Revest, C. Jacqueline, R. Boudjemaa, J. Caillon, V. Le Mabecque, A. Breteche, K. Steenkeste, P. Tattevin, G. Potel, C. Michelet, M. P. Fontaine-Aupart and D. Boutoille
"2014 - Impact of bacterial biofilm on the treatment of prosthetic joint infections. J. Antimicrob Chemother, Journal of Antimicrobial Chemotherapy"
Cédric Jacqueline and Jocelyne Caillon
"2014 - Linezolid Dampens Neutrophil-Mediated Inflammation in Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia and Protects the Lung of Associated Damages"
Cédric Jacqueline, Alexis Broquet, Antoine Roquilly, Marion Davieau,1 Jocelyne Caillon, Frédéric Altare, Gilles Potel, and Karim Asehnoune
For more publications, please login to 
of Jocelyne Caillon, Gilles Potel, Karim Asehnoune or Cédric Jaqueline.
CONTACT US
+33 610 341 744
contact@atlangram.com
ATLANGRAM
Nantes Biotech Business
22 Boulevard Benoni GOULLIN
44200 NANTES - FRANCE
Mentions légales
